Improving cardiorenal outcomes in type 2 diabetes: real-world implementation and population-level impact of SLGT2 inhibitors and GLP-1 receptor agonists
Description: Heart and kidney disease are leading causes of death in type 2 diabetes. New medications that significantly reduce these risks remain vastly underused in the real world, particularly in those who are at highest risk. This PhD will use Australian and global big data to assess the real-world effectiveness of these therapies, uncover disparities in access, and generate evidence to guide more targeted and equitable use to improve population-level outcomes for those living with type 2 diabetes.
Amount: A$163,400
Funding type: fellowship
Funder scheme: Postgraduate Scholarships - Postgraduate Scholarships
Start date: 2026-01-01
End date: 2028-12-31
Investigator: Beryl Lin
Institution: Baker Heart and Diabetes Institute
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Funded outputs count: 0
Funder award ID: 2049753
OpenAlex ID: G1997516777